2026-07-06T13:04:55-04:00 2025-10-31 873393377 SMART SOLUTIONS CPA INC 1 E ERIE ST STE 525-2419 Chicago IL 60611 990 2024-11-01 363719712 THE KIDNEY CANCER ASSOCIATION % GRETCHEN E VAUGHAN KIDN 8008509132 PO BOX 676226 DALLAS TX 75267 GRETCHEN E VAUGHAN PRESIDENT & CEO 8008509132 2026-06-04 false true NOMAN TAHIR P02060413 3123130650 2026-07-06 2024 2025-03-06 01:10:19Z 4936373 false X WWW.KIDNEYCANCER.ORG X 1990 IL THE KIDNEY CANCER ASSOCIATION IS A GLOBAL COMMUNITY DEDICATED TO SERVING AND EMPOWERING PATIENTS, AND LEADING CHANGE THROUGH ADVOCACY, RESEARCH, AND EDUCATION IN ORDER TO BE THE UNIVERSAL LEADER IN FINDING THE CURE FOR KIDNEY CANCER. 16 16 16 206 0 0 3468895 3471097 249037 282399 1191650 730749 32447 450195 4942029 4934440 387698 458325 0 2669682 2549340 0 459739 2216230 2893043 5273610 5900708 -331581 -966268 26510439 28252813 1672474 2094422 24837965 26158391 THE KIDNEY CANCER ASSOCIATION IS A GLOBAL COMMUNITY DEDICATED TO SERVING AND EMPOWERING PATIENTS, AND LEADING CHANGE THROUGH ADVOCACY, RESEARCH, AND EDUCATION IN ORDER TO BE THE UNIVERSAL LEADER IN FINDING THE CURE FOR KIDNEY CANCER. false false 2237246 EDUCATION - THE KIDNEY CANCER ASSOCIATION PROVIDES OPPORTUNITIES FOR PHYSICIANS, RESEARCHERS, ACADEMICS, AND INDUSTRY PROFESSIONALS FROM ACROSS THE GLOBE TO COME TOGETHER AND EXCHANGE IDEAS THAT WILL DIRECT THE FUTURE OF KIDNEY CANCER RESEARCH AND TREATMENT IN THE ULTIMATE PURSUIT OF A CURE. THE PRIMARY OPPORTUNITIES ARE DURING THE TWO ANNUAL SYMPOSIA, IKCS NORTH AMERICA AND IKCS EUROPE, HELD BOTH IN PERSON. IKCS MEETINGS PROMOTE LEARNING, NETWORKING, AND UNPARALLELED OPPORTUNITIES FOR MENTORSHIP AND COLLABORATION. 1497880 38064 281639 PATIENT SUPPORT AND ADVOCACY - THE KIDNEY CANCER ASSOCIATION SEEKS TO BE A SOURCE OF EDUCATION AND RESOURCES FOR PATIENTS, CAREGIVERS, AND ANYONE IMPACTED BY KIDNEY CANCER. THE KCA PROVIDES PATIENT RESOURCES FOR EACH STAGE OF THE KIDNEY CANCER JOURNEY INCLUDING OUR JUST DIAGNOSED TOOLKIT, PATIENT NAVIGATOR PROGRAM, VIRTUAL PATIENT SYMPOSIUM, KCA CONNECT, PATIENT ASSISTANCE FUND, AND EDUCATIONAL RESOURCES INCLUDING INFORMATION ON TREATMENTS, DRUGS, CLINICAL TRIALS, AND CAREGIVING TO NAME A FEW. 1210399 420261 RESEARCH - THE KIDNEY CANCER ASSOCIATION IS COMMITTED TO SUPPORTING HEALTHCARE PROFESSIONALS, FOSTERING PROFESSIONAL COLLABORATION, AND FUNDING RESEARCH THAT ADVANCES OUR UNDERSTANDING OF KIDNEY CANCER. THE ORGANIZATION AWARDED GRANTS TO PHYSICIANS AND SCIENTISTS ENGAGED IN RESEARCH TARGETING EARLY DETECTION AND INNOVATIVE TREATMENTS FOR KIDNEY CANCER. 4945525 true true false false false false false false false true true false false false true true true false false false true true false false false false false true true true false false false false false false false false true false false false false false false false false true 5 0 16 true false false false false false false false false false false false false X 16 16 false false false false false false false true false false false true true true true true true true true false IL X GRETCHEN E VAUGHAN 8008509132 277 ALLEN PKWY HOUSTON TX 77019 GRETCHEN E VAUGHAN PRESIDENT & CEO 40.00 0.00 X X 355063 0 27909 SALVATORE LA ROSA CHIEF SCIENTIFIC OFFICER 40.00 0.00 X 269537 0 24485 KENDALL MONROE CHIEF ADVANCEMENT OFFICER 40.00 0.00 X 248498 0 26525 RADHA CHITALE SR DIRECTOR OF COMMUNICATIONS 40.00 0.00 X 131060 0 17936 ANGELA WASHINGTON DIRECTOR OF OPERATIONS 40.00 0.00 X 126087 0 17687 AMY MARBAUGH SENIOR DIRECTOR OF PATIENT PROGRAMS 40.00 0.00 X 105164 0 15013 BRADLEY LEIBOVICH MD BOARD CHAIR 1.00 0.00 X 0 0 0 RYAN NATZKE VICE CHAIR 0.50 0.00 X 0 0 0 JOEL STERN TREASURER 1.00 0.00 X 0 0 0 TESSA CHURCHILL MD SECRETARY 0.50 0.00 X 0 0 0 LAURENCE ALBIGES MD PHD DIRECTOR 0.50 0.00 X 0 0 0 MAHUL B AMIN MD DIRECTOR 0.50 0.00 X 0 0 0 NOAH BUNTMAN DIRECTOR 0.50 0.00 X 0 0 0 RONALD BUKOWSKI MD DIRECTOR 0.50 0.00 X 0 0 0 CRAIG DEPRIESTER DIRECTOR 0.50 0.00 X 0 0 0 DANIEL GEORGE MD DIRECTOR 0.50 0.00 X 0 0 0 JAMIE GRAVES DIRECTOR 0.50 0.00 X 0 0 0 DAVID PERRY ESQ DIRECTOR 0.50 0.00 X 0 0 0 SHELLEY ROBSON DIRECTOR 0.50 0.00 X 0 0 0 BRIAN SHUCH MD DIRECTOR 0.50 0.00 X 0 0 0 LAURA WOOD RN DIRECTOR 0.50 0.00 X 0 0 0 RUBEN YBARRA DIRECTOR 0.50 0.00 X 0 0 0 1235409 0 129555 6 false true false CHRISTOPHER SHELTON 1311 HASTINGS DR VALDOSTA GA 31601 EVENT PLANNING 155496 JEANETTE STENSGAARD 27022 DAVIES AVE AURORA CO 80016 EVENT PLANNING 135000 2 3471097 205345 3471097 SYMPOSIA REGISTRATIONS 611710 282399 282399 282399 730749 730749 0 1173 1933 -760 -760 MISCELLANEOUS INCOME 900099 27467 27467 REALIZED GAIN FROM SECU 900099 423039 423039 EXCHANGE GAIN OR LOSS 900099 419 419 30 30 450955 4934440 281639 0 1181704 420261 420261 38064 38064 1292869 980900 144155 167814 831921 631179 92759 107983 85330 64740 9514 11076 191798 145518 21385 24895 147422 111849 16438 19135 48678 36932 5428 6318 27469 27299 170 131551 99808 14668 17075 47073 47073 562898 517536 3468 41894 76307 50349 384 25574 32433 20009 10583 1841 195511 154006 11959 29546 58321 58321 249895 231568 18031 296 1675 787 250 638 2326 1047 1134 145 8260 6418 851 991 EDUCATION PROGRAMS 1028609 1028609 PATIENT PROGRAMS 43189 43189 RESEARCH EXPENSES 198855 198855 LICENSE AND PERMITS 13944 10579 1555 1810 166049 126023 37318 2708 5900708 4945525 495444 459739 589406 188060 1274647 1837093 114597 116557 299537 346635 16287 12798 5816 3489 23548084 25097181 678352 663798 26510439 28252813 377475 570768 375000 1146878 1029422 148121 119232 1672474 2094422 X 23684171 24960551 1153794 1197840 24837965 26158391 26510439 28252813 X -966268 2273355 13339 X false true X true false X 2826146 2818520 2903367 3468895 3471097 15488025 2826146 2818520 2903367 3468895 3471097 15488025 138866 15349159 463048 703006 678656 749101 730749 3324560 251669 7015 100633 18775 450195 828287 19640872 0.78150 0.57140 X Other income Part II line 10 or Part III line 12 OTHER GROSS INCOME2019 AMOUNT: $ 1,405.2020 AMOUNT: $ 251,669.2021 AMOUNT: $ 9,657.2022 AMOUNT: $ 108,486.2023 AMOUNT: $ 18,820.2024 AMOUNT: $ 450,195.(LOSS)/GAIN ON EXCHANGE RATES2021 AMOUNT: $ -2,642.2022 AMOUNT: $ -7,853.2023 AMOUNT: $ -45.2024 AMOUNT: $ 419. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 20561293 111255 2894531 1477109 741767 21348203 17027165 285616 4234722 386210 600000 20561293 16678507 36208 1137450 375000 450000 17027165 21581262 172629 -3850384 1225000 16678507 17837624 3743638 21581262 0.97210 0.02510 0.00280 false false 16287 12798 3489 3489 LEASE LIABILITY - OPERATING 88140 OPERATING LEASE LIABILITY- CURRENT 31092 119232 X 7175994 2273355 13339 2286694 4889300 47073 -1933 45140 4934440 5855568 5855568 47073 -1933 45140 5900708 Part V, Line 4-Intended uses of endowment funds THE ASSOCIATION ESTABLISHED A RESERVE TO FUND FUTURE OPERATIONS AND AN ENDOWMENT FUND FOR RESEARCH AND PATIENT SERVICES. IN 2022, THE ASSOCIATION ESTABLISHED AN ENDOWMENT FUND AND RECEIVED CERTAIN GIFTS FROM THE DONOR TO BE MAINTAINED IN PERPETUITY. Part XI, Line 2d-Other revenue included on Sch D but not on 990 CHANGE IN VALUE - SPLIT INTEREST AGREEMENT $13339 Part XI, Line 4b-Other revenue not included on Sch D but on 990 COST OF GOODS SOLD -$1,933 Part XII, Line 4b-Other expenses not included on Sch D but on 990 COST OF GOODS SOLD -$1,933 Part X, Line 2-Text in footnote regarding FIN 48 (ASC 740) THE ASSOCIATION QUALIFIES AS A TAX-EXEMPT ORGANIZATION UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND, THEREFORE, HAS NO PROVISION FOR FEDERAL INCOME TAXES. IT IS ALSO EXEMPT FROM STATE INCOME TAX UNDER THE ILLINOIS CHARITABLE TRUST ACT.THE ASSOCIATION FOLLOWS THE GUIDANCE OF ACCOUNTING STANDARDS CODIFICATION (ASC) 740, ACCOUNTING FOR INCOME TAXES, RELATED TO UNCERTAINTIES IN INCOME TAXES, WHICH PRESCRIBES A THRESHOLD OF MORE LIKELY THAN NOT FOR RECOGNITION AND DERECOGNITION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE ARE NO SUCH UNCERTAIN TAX POSITIONS FOR THE ASSOCIATION FOR THE YEARS ENDED OCTOBER 31, 2025 AND 2024. EUROPE INCLUDING ICELAND AND GREENLAND PROGRAM SERVICES INTERNATIONAL KIDNEY 368000 368000 368000 EUROPE INCLUDING ICELAND AND GREENLAND RESEARCH 39625 EFT false false false false false false true CANCER RESEARCH INSTITUTE 29 BROADWAY FLOOR 4 NEW YORK NY 10006 131837442 501C3 75000 NA NA RESEARCH THE UNIVERSITY OF TEXAS MD ANDERSON 1515 HOLCOMBE BOULEVARD UNIT 1697 HOUSTON TX 77030 746001118 UNIVERSITY OF T 75000 NA NA RESEARCH COLD SPRING HARBOR LABORATORY 1 BUNGTOWN RD PO BOX 100 COLD SPRING HARBOR NY 11724 112013303 501C3 75000 NA NA RESEARCH MEMORIAL SLOAN KETTERING CANCER CEN 1275 YORK AVENUE NEW YORK NY 10065 131624182 501C3 75000 NA NA RESEARCH BECKMAN RESEARCH INSTITUTE OF THE C 1450 EAST DUARTE ROAD DUARTE CA 91010 953432210 501C3 75000 NA NA RESEARCH HEALTH RESEARCH INC 150 BROADWAY 280 MENANDS NY 12204 141402155 501C3 75000 NA NA RESEARCH PATIENT ASSISTANCE VISA GIFT CARDS 124 44158 NA NA Monitoring procedures (Part I, line 2) THE GRANT REVIEW PROCESS THOROUGHLY VETS GRANT APPLICANTS. IF SELECTED TO RECEIVE A KCA RESEARCH GRANT, THE GRANTEE MUST SIGN A KCA GRANT ACCEPTANCE AGREEMENT TERMS AND CONDITIONS. THIS AGREEMENT REQUIRES THE GRANTEE TO SUBMIT A GRANT PROGRESS REPORT WITH OUTCOMES, POSSIBLE FUTURE RESEARCH DIRECTIONS, REFLECTIVE IMPACT STATEMENT, AND AN ACCOUNTING OF HOW THE GRANT FUNDS WERE USED.THROUGH OUR PATIENT ASSISTANCE FUND, WE HELP KIDNEY CANCER PATIENTS OFFSET COSTS THEY INCUR WHEN GETTING TREATMENT LIKE PARKING, MEALS, ETC. WE SEND THEM A KCA BRANDED VISA GIFT CARD IN EITHER A $50 OR $250 AMOUNT BASED ON THEIR NEED. WE ALSO WORK DIRECTLY WITH TREATMENT FACILITIES TO PROVIDE $25 KCA BRANDED VISA GIFT CARDS TO KIDNEY CANCER PATIENTS WHILE THEY ARE AT THE FACILITY RECEIVING TREATMENT. X X X false false false false false false false false false GRETCHEN E VAUGHAN PRESIDENT & CEO 355063 27909 382972 KENDALL MONROE CHIEF ADVANCEMENT OFFICER 248498 26525 275023 SALVATORE LA ROSA CHIEF SCIENTIFIC OFFICER 269537 24485 294022 X 5 199229 FMV false false false Committee meeting documentation Part VI line 8b THE ORGANIZATION DOES NOT HAVE A COMMITTEE WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. Form 990 governing body review Part VI line 11 THE 990 IS REVIEWED IN DETAIL BY THE CHIEF FINANCIAL AND OPERATING OFFICER AND THE PRESIDENT/CEO BEFORE SIGNING. THE RETURN IS MADE AVAILABLE TO THE FULL BOARD OF DIRECTORS TO REVIEW VIA EMAIL BEFORE IT IS FILED. Conflict of interest policy compliance Part VI line 12c THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY THAT REQUIRES EMPLOYEES AND BOARD MEMBERS TO ANNUALLY DISCLOSE INTERESTS THAT COULD GIVE RISE TO CONFLICTS. AT THE NOVEMBER BOARD MEETING, EVERY BOARD MEMBER IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST QUESTIONNAIRE ACKNOWLEDGING THEY UNDERSTAND THE POLICY AND DISCLOSING ANY CONFLICTS OF INTEREST THEY ARE AWARE OF. THROUGHOUT THE YEAR, SIGNIFICANT CONTRACTS AND TRANSACTIONS ARE REVIEWED BY THE CHIEF FINANCIAL AND OPERATING OFFICER AND THE PRESIDENT/CEO FOR POTENTIAL CONFLICTS. IF AN ACTUAL OR POTENTIAL CONFLICT IS IDENTIFIED, THE ASSOCIATION ACQUIRES AT LEAST TWO OTHER QUOTES TO PRESENT TO THE FINANCE COMMITTEE FOR APPROVAL PRIOR TO RATIFYING WITH THE BOARD OF DIRECTORS. THE CONFLICTED MEMBER IS RECUSED FROM VOTING ON MATTERS IN WHICH THE CONFLICT IS IDENTIFIED. CEO executive director top management comp Part VI line 15a THE BOARD CHAIR AND THE NOMINATING AND GOVERNANCE COMMITTEE (NGC) IS RESPONSIBLE FOR ADMINISTERING THE ANNUAL PERFORMANCE EVALUATION OF THE PRESIDENT/CEO. THE NGC REVIEWS COMPENSATION DATA THAT IS AVAILABLE ON SITES LIKE CHARITY NAVIGATOR AND GUIDESTAR AS WELL AS THE 990 RETURNS OF SIMILAR NONPROFIT ORGANIZATIONS. THE NGC MAKES A RECOMMENDATION TO THE BOARD AND THE BOARD VOTES ON THE COMPENSATION OF THE PRESIDENT/CEO. Other officer or key employee compensation Part VI line 15b THE PRESIDENT/CEO, CHIEF ADVANCEMENT OFFICER, CHIEF SCIENTIFIC OFFICER, DIRECTOR OF OPERATIONS, AND CHIEF FINANCIAL AND OPERATING OFFICER WORKED TOGETHER TO REVIEW THE MERIT INCREASES AND BONUSES OF THE STAFF. THE FACTORS CONSIDERED IN AWARDING INCREASES WAS PERFORMANCE REVIEW RATING, ACCOMPLISHMENT OF GOALS, LENGTH OF SERVICE, ANY RECENT PROMOTIONS, AND THE APPROVED ANNUAL BUDGET. Governing documents etc available to public Part VI line 19 THE ORGANIZATION MAKES ITS BY-LAWS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE GENERAL PUBLIC UPON REQUEST. Explanation of other changes in net assets or fund balances Part XI line 9 CHANGE IN VALUE - SPLIT INTEREST AGREEMENT $13339.